The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

PET studies in Alzheimer Disease and Other Degenerative Dementias

알쯔하이머병과 다른 퇴행성 치매에서의 양전자방출단층촬영

  • Jeong, Yong (Department of Neurology, Samsung Medical Center, School of Medicine, Sungkyunkwan University) ;
  • Na, Duk-L. (Department of Neurology, Samsung Medical Center, School of Medicine, Sungkyunkwan University)
  • 정용 (성균관대학교 의과대학 삼성서울병원 신경과학 교실) ;
  • 나덕렬 (성균관대학교 의과대학 삼성서울병원 신경과학 교실)
  • Published : 2003.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Neurodegenerative disorders cause a variety of dementia including Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, and Huntington's disease. PET scan is useful for early detection and differential diagnosis of these dementing disorders. Also, it provides valuable information about clinico-anatomical correlation, allowing better understanding of function of brain. Here we discuss recent achievements PET studies regarding these dementing disorders. Future progress in PET technology, new tracers, and image analysis will play an important role in further clarifying the disease pathophysiology and brain functions.

Keywords

References

  1. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45-50
  2. Metter EJ, Mazziotta IC, Itabashi HH, Mankovich NI, Phelps ME, Kuhl DE. Comparison of glucose metabolism, x-ray CT, and postmortem data in a patient with multiple cerebral infarcts. Neurology 1985;35: 1695-1701
  3. Tedeschi E, Hasselbalch SG, Waldemar G, Juhler M, Hogh P, Holm S, et al. Heterogenous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 1995;59:608-615
  4. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the quality standards subcommittee of the American Academy of Neurology Neurology 2001;56;1143-1153
  5. Patterson C, Gauthier S, Bergman H, Cohen C, Feightner JW, Feldman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci 2001;28(Suppl 1):S3-16
  6. Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186: 17-20
  7. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:494-504
  8. McKhann G, Drachman D, Folstein M, Katzman R, Price -0, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
  9. American Psychiatry Association. Diagnostic and statistical Manual of Mental Disorders, 3rd ed. revised. American Psychiatry Association. 1987, Washington, D.C
  10. American Psychiatry Association. Diagnostic and statistical Manual of Mental Disorders, 4th ed. American Psychiatry Association. 1994, Washington, D.C
  11. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 1983;7:590-598
  12. Hoffman JM, Hanson MW, Welsh KA, Earl N, Paine S, Delong D, et al. Interpretation variability of 18PDG-positron emission tomography studies in dementia. Invest Radiol 1996;31:316-322
  13. Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, et al. Comparability of PDG PET studies in probable Alzheimer's disease. J Nucl Med 1993;34: 1460-1466
  14. Kim SE, Na DL, Lee J, Choi Y, Lee KH, Choe YS et al. Assessment of metabolic impairment in Alzheimer's disease with [18F]FDG-PET: Validity and role of simplified tissue radioactivity ratio analysis. Korean J Nucl Med 1996;30:299-314
  15. Jeong Y, Han DH, Yi HA, Cho SS, Chin J, Kang SJ, et al. Neuropsychological and Neuroimaging Findings of Frontal Variant of Alzheimer's Disease. J Korean Neurol Assoc 2003;21:32-40
  16. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab 1985;5: 193-200
  17. Salmon E, Sadzot B, Maquet P, Degueldre C, Lemaire C, Rigo P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 1994;35:391-398
  18. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-466
  19. Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 1982;2: 163-171
  20. Duara R, Grady C, Haxby J, Ingvar D, Sokoloff L, Margolin RA, et al. Human brain glucose utilization and cognitive function in relation to age. Ann Neurol 1984;16:703-713
  21. Duara R, Margolin RA, Robertson-Tchabo EA, London ED, Schwartz M, Renfrew JW, et al. Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years. Brain 1983;106:761-775
  22. Cutler NR, Haxby JV, Duara R, Grady CL, Moore AM, Parisi JE, et al. Brain metabolism as measured with positron emission tomography: serial assessment in a patient with familial Alzheimer's disease. Neurology 1985;35:1556-1561
  23. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 1992;13:93-98
  24. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 1983;33:961-965
  25. Akiyama H, Harrop R, McGeer PL, Peppard R, McGeer EG. Crossed cerebellar and uncrossed basal ganglia and thalamic diaschisis in Alzheimer's disease. Neurology 1989;39:541-548
  26. Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol 1984;16:649-654
  27. Mayeux R, Sano M. Treatment' of Alzheimer's disease. New Eng J Med 2000;341:1670-1679
  28. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94
  29. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D; Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996 21;334:752-758
  30. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308
  31. Neary D, Snowden JS, Mann DM, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53:23-32
  32. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554
  33. Varma AR. Snowden JS. Lloyd JJ. Talbot PR Mann DM. Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999;66:184-188
  34. Ishii 1(, Sakamoto S, SasakiM, Kitagaki H, Yarnaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998;39:1875-1878
  35. Edwards-Lee T, Miller BL, Benson DF, Cummings JL, Russell GL, Boone K, et al. The temporal variant of frontotemporal dementia. Brain 1997;120:1027-1040
  36. Garraux G, Salmon E, Degueldre C, Lemaire C, Franck G. Medial temporal lobe metabolic impairment in dementia associated with motor neuron disease. J Neurol Sci 1999;168:145-150
  37. Tyrrell PI, Warrington EK, Frackowiak RS, Rossor MN. Heterogeneity in progressive aphasia due to focal cortical atrophy. A clinical and PET study. Brain 1990;113:1321-1336
  38. Kwon JC, Kang SJ, Chin J, Kang Y, Lee YM, Kim H, et al. Neuropsychological and neuroimaging fmdings of semantic dementia. J Korean Neurol Assoc 2001;19:598-607
  39. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
  40. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry 2002;180:144-147
  41. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigrnine in dementia with l..ewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036
  42. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000;15:794-802
  43. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117: 1183-1196
  44. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992;7:348-354
  45. Yamauchi H, Fukuyama H, Nagahama Y, Katsumi Y, Dong Y, Hayashi T, et al. Atrophy of the corpus callosum, cortical hypometabolism, and cognitive impairment in corticobasal degeneration. Arch Neurol 1998;55:609-614
  46. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54: 856-862
  47. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RS. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991;114:541-556
  48. Steel JC, Richardson JC, Olszewski. Progressive supranuclear palsy; a heterogenous degeneraton involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementa. Arch Neurol 1964;10:333-359
  49. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron mission tomography. Ann Neurol 1988;24:399-406
  50. Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, Agid Y. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747-752
  51. Litvan I. Cognitive disturbances in progressive supranuclear palsy. J Neural Transm Suppl 1994;42: 69-78
  52. Leenders KL, Frackowiak RS, Lees AI. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 1988; 111:615-630
  53. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993 26;72:971-983
  54. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986;20:296-303
  55. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;316:357-362
  56. Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahi E, et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 1997;8:78-84
  57. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699
  58. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35